Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has submitted a nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting in North Bethesda, US.
Subscribe to our email newsletter
PV-10 is a new oncology drug that selectively targets and destroys cancer cells without harming surrounding healthy tissue, thereby reducing potential for systemic side effects.
The data titled "Generation of an antitumor response and immunity using a small molecule drug (PV-10)" was presented by Dr. Craig Dees and Savannah Blair of Provectus.
The PV-10’s bystander effect was investigated using hepatocellular carcinoma (HCC) and melanoma tumors in immunocompetent and immunodeficient mice.
Provectus Pharmaceuticals CEO Craig Dees said the data presented at SITC indicates that PV-10 can reduce tumor burden in consistent with an immunologic response to the ablated tumor.
”This immuno-chemoablative effect is consistent with bystander responses we’ve seen in clinical trials of PV-10 for melanoma and HCC,” Dees added.
”Potential synergy from combination of PV-10 with systemic therapy is demonstrated by the enhanced response of uninjected tumors over that achieved with PV-10 alone."